WebApr 10, 2024 · Year End Cash Balance of $17.1 Million. BERKELEY, US - MAINZ, Germany - April 10, 2024 - Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the … WebAug 16, 2024 · About Mainz Biomed N.V. Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non ...
Mainz Biomed Recognizes Colorectal Cancer Awareness Month
WebApr 10, 2024 · Year End Cash Balance of $17.1 Million. BERKELEY, Calif. and MAINZ, Germany, April 10, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. MYNZ (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the fiscal year ended … WebFeb 21, 2024 · BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the execution of its option from Uni Targeting Research AS to … immj2 telly update
EQS-News: Mainz Biomed Reports Positive Results from …
WebApr 10, 2024 · Year End Cash Balance of $17.1 Million. BERKELEY, Calif. and MAINZ, Germany, April 10, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular ... Web21 hours ago · The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mainz Biomed B.V. with a $18.00 average price target, which is a … WebMainz, Germany. Mainz Biomed ( NASDAQ: MYNZ) is located just west of Frankfurt in a world-renowned community for advanced DNA & Pharmaceutical research, including the home of vaccine maker BioNTech SE. The TÜV Rheinland certifies that Mainz Biomed manufactures ColoAlert according to DIN EN ISO 13485. Click here to view certificate. immj 2 telly updates